AS
Astec Lifesciences Ltd (ASTEC)
₹541.70
Mkt cap
₹1,230 Cr
P/E ratio
—
P/B
3.61
Div yield
0.00%
ROE
−25.20%
ROCE
−5.44%
EPS (TTM)
—
Book value
₹150
52W range
510–942
Sector
Commodities
Price history
Previous close
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B). [1] [2] [3]
NSE ASTECBSE 533138
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−42.48% from high₹542
₹510+6.30% from low₹942
Current
₹541.70
Prev close
₹552.45
Day
−1.95%
Price performance
1D
−1.71%
1W
−1.60%
1M
−18.86%
3M
−9.77%
6M
−26.29%
1Y
−14.06%
YTD
−24.25%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 | 72 | |
| YoY Sales growth | -45% | -57% | +21% | -51% | -11% | +85% | -22% | +31% | -25% | +33% | +33% | -8% | -2% | |
| Expenses | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 | 92 | |
| Operating Profit | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 | -7 | 4 | 9 | -1 | -20 | |
| OPM % | -3.1% | -36% | 8% | -67% | -20% | -6% | 4.6% | -12% | -9% | 3.2% | 6% | -0.8% | -27% | |
| Other Income | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | -1 | 3 | 1 | 1 | |
| Interest | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 | 7 | |
| Depreciation | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 | 11 | |
| Profit before tax | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 | -24 | -16 | -8 | -19 | -37 | |
| Tax % | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% | 0% | 0% | -2% | -0% | -0% | |
| Net Profit | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 | -37 | |
| EPS in Rs | -6.78 | -12.29 | -0.49 | -20.06 | -19.47 | -20.39 | -8.13 | -16.69 | -10.96 | -7.05 | -3.48 | -8.40 | -16.79 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202671.97%Promoter
Promoters71.97%
FIIs0.02%0.01
DIIs3.34%
Public24.67%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| UPL | ₹559.40 | 24.67 | 47,208 | 1.07% | 452 | −12.95% | 11,860 | −1.32% | 10.11% |
| P I Industries | ₹1,714.80 | 32.81 | 26,017 | 0.87% | 122 | −70.14% | 1,702 | −9.11% | 14.99% |
| Sumitomo Chemi. | ₹346.60 | 31.49 | 17,300 | 0.38% | 156 | −12.29% | 891 | −2.57% | 23.48% |
| Bayer Crop Sci. | ₹3,447.00 | 20.78 | 15,492 | 4.35% | 166 | +8.84% | 1,251 | −19.49% | 29.14% |
| Sharda Cropchem | ₹730.50 | 10.24 | 6,591 | 2.05% | 92 | +23.52% | 1,052 | +13.19% | 30.25% |
| Dhanuka Agritech | ₹907.85 | 14.29 | 4,047 | 0.22% | 109 | +16.23% | 658 | +9.91% | 23.76% |
| Rallis India | ₹189.25 | 17.92 | 3,680 | 1.59% | 85 | −23.62% | 858 | −0.35% | 14.14% |
| Astec Lifescienc | ₹551.85 | — | 1,230 | 0.00% | −37 | −53.13% | 72 | −2.31% | −5.44% |
| Median: 25 Co. | ₹238.85 | 18.06 | 1,412 | 0.16% | 25 | −3.25% | 372 | +4.27% | 14.99% |
Filings
Annual reports15
Concall transcripts6
Credit ratings6
Announcements5
Reply To Volume Movement Letter 12 Nov - Astec confirms compliance and no undisclosed events behind recent volume spike.Clarification sought from Astec Lifesciences Ltd 11 Nov - Exchange has sought clarification from Astec Lifesciences Ltd on November 11, 2026, with reference to Movement in Volume.Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Oct - Please find enclosed, newspaper publication of Financial Results for the Quarter and Half Year ended September 30, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 26 Oct - Astec Lifesciences approved Q2 and H1 FY27 results; Q2 revenue ₹72.6 crore, PAT loss ₹37.4 crore.Financials Results 26 Oct - Board approved Q2 FY26 results; standalone loss Rs 3,746.96 lakh, consolidated loss Rs 3,742.78 lakh.






